Date published: 2026-5-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

CCDC18 Inhibitors

CCDC18 inhibitors are chemical compounds that play a crucial role in downregulating the functional activity of CCDC18 through their effects on various cellular signaling pathways. For instance, PD 98059 and SB 203580, by inhibiting MEK and p38 MAPK respectively, create an environment that reduces cellular growth and stress responses, pathways in which CCDC18 is implicated. Similarly, LY 294002 and Rapamycin target the PI3K/Akt and mTOR pathways, which are pivotal for cell survival and proliferation, processes that are essential for the proper activity of CCDC18. Bortezomib, through proteasome inhibition, disrupts protein degradation mechanisms, leading to a decrease in CCDC18 activity which is reliant on protein turnover. In contrast, WZB117 limits energy supply by inhibiting GLUT1, suggesting that the energy-intensive processes governed by CCDC18 are indirectly curtailed.

The impact of these inhibitors extends to cell cycle regulation, with compounds like PD 0332991 halting the progression from G1 to S phase, thus causing areduction in the regulatory influence of CCDC18 on cell division. Triciribine and SP600125 add to this inhibitory arsenal by targeting Akt and JNK pathways, respectively, which are crucial for the survival and proliferation of cells, and possibly for the functional efficacy of CCDC18. The influence of Sunitinib and Sorafenib stretches to angiogenesis and cell migration, where CCDC18 might play a role; by attenuating receptor tyrosine kinase and RAF/MEK/ERK signaling, these inhibitors can indirectly limit the functional terrain of CCDC18. Lastly, Gefitinib's impairment of EGFR signaling further contributes to the spectrum of inhibition, encapsulating the multifaceted approach required to diminish the activity of CCDC18, which is likely implicated in a variety of cellular processes, including cell proliferation and survival. Collectively, these inhibitors work synergistically to curtail the functional activity of CCDC18, providing insight into the complex regulation of cellular mechanisms where CCDC18 is involved.

SEE ALSO...

Items 11 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

An EGFR inhibitor that impairs the EGFR signaling pathway. Diminishing EGFR signaling can lead to reduced cell proliferation and survival, indirectly affecting CCDC18's associated processes.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

A multi-kinase inhibitor that affects RAF/MEK/ERK signaling. By inhibiting this pathway, the cell proliferation and angiogenesis processes that CCDC18 might be involved in are indirectly diminished.